{"name":"Alizyme","slug":"alizyme","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ATL-104","genericName":"ATL-104","slug":"atl-104","indication":"Type 2 diabetes","status":"phase_2"},{"name":"ATL-962","genericName":"ATL-962","slug":"atl-962","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ATL-104","genericName":"ATL-104","slug":"atl-104","phase":"phase_2","mechanism":"ATL-104 is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ATL-962","genericName":"ATL-962","slug":"atl-962","phase":"phase_2","mechanism":"ATL-962 is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNT1d1VDVrVUFBUXVnS1RBSjRfZnB2OUxXMnJneC11XzlhV3g5WkE5UUUzUVlnYVFJQ05VdXpEdU9oWkJzNU1CTnlJa2N2dnNDRkw4UkxFam9TZWgwem5YSkdQNXBsMUszYjZCZTZjSjJMZGYyZkN1RUM2RENQbUdadldLWEZiZnFLYTd2NG1XR2V1NXBkNWtKUDFGWGJsTnNSUDNrSExzbWF3Z2dTT1VyUDRmOWRDRFl2cWxjZDh6UGJzZGVUMHI4RmJpM1dackhFVkJ3VFppNkFjT3VLNUwtZ1pjMXFDVGRmZzQzYkdXdl83SjlhTnVsM0x0cjMtdE04VXJBNVdxc09aSXZNWk02OGdidGp5SGE5VjdZNWVmRXFLdXJzN0hmY1Y0VnZPemVnOXVrZHRpbmFpNW5SR2JlT3ZMQ1hfcWNDcU9z?oc=5","date":"2026-04-03","type":"regulatory","source":"Barchart.com","summary":"Obesity Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma, Roche - Ba","headline":"Obesity Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBqWGZRY2tnWFhGTHJHRFkwTHAzYzJMTXM2aUxzR1ZMVmJmYjYxd3cxZVBRRllBU0V4LUNnSmlkZ0dwSXQ0cEU0VTJ3RGZ0YTlRT3d6RzgyZ0NvN1MwNzlwTDBxYnE2T3ZpV3c?oc=5","date":"2013-01-13","type":"trial","source":"Clinical Trials Arena","summary":"Cetilistat – Investigational Drug for Obesity - Clinical Trials Arena","headline":"Cetilistat – Investigational Drug for Obesity","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}